2012年3月20日 · Purpose: Cardiac involvement predicts poor prognosis in light chain (AL) amyloidosis, and the current prognostic classification is based on cardiac biomarkers troponin-T (cTnT) and N-terminal pro-B-type natriuretic peptide (NT-ProBNP).

梅奥2012分期标准为 ：按照患者具有以下危险因素的数量（0~3个）将其分为1~4期：NT-proBNP≥1 800 ng/L、cTnI≥0.08 mg/L、FLC差值（dFLC，异常FLC值减去正常FLC值）≥180 mg/L。

2023年11月2日 · The Mayo 2012 staging, utilising additional dFLC, did not discriminate the most advanced disease as well suggesting that treatment markedly impacts the predictive capability of cardiac staging systems.

2019年2月14日 · The European 2015 model was built on the Mayo 2004 model and subclassifies stage III patients into higher- and lower-risk categories by incorporating a second NT-proBNP threshold of 8500 ng/L 2 .The Mayo 2012 system uses different thresholds for NT-proBNP and cTnT, and it incorporates serum free light chain level as additional risk factor. 18 A ...

2025年2月5日 · Re-evaluation of Mayo 2004 and revised Mayo 2012 staging in patients with AL amyloidosis in the era of new therapies Amyloid . 2025 Feb 4:1-3. doi: 10.1080/13506129.2025.2456790.

研究结果表明，Mayo 2012心脏分级系统在高级心脏AL淀粉样变性患者风险分层中的有效性有限。 具体来说，这种系统无法准确预测患者的生存期和治疗反应。

2024年5月5日 · It has been suggested that the Mayo 2012 staging system predicts late survival more accurately and the European modification predicts early mortality; the current data confirm these observations. The Mayo system gives equal weighting to plasma cell burden (dFLC) and each cardiac biomarker.

At multivariate analysis, decreased eGFR retained an independent prognostic value with the Mayo2004 and Mayo 2012 staging systems, but not with the Mayo2004/European system. Atrial arrhythmia reduced the discriminating ability of all three staging systems, with a more pronounced impact on the Mayo2012 system.

This revised Mayo staging system for AL amyloidosis allows us to better discriminate between groups with different outcomes, enabling better prognostic classification. The model seems to be generalizable to a wide spectrum of patients, which should encourage routine incorporation into clinical trials, thus allowing better comparison of results ...

Limited utility of Mayo 2012 cardiac staging system for risk stratification of patients with advanced cardiac AL amyloidosis - analysis of a uniformly treated cohort of 1,275 patients Haematologica . 2024 May 1;109(5):1598-1602. doi: 10.3324/haematol.2023.284348.